Welcome to AmPolGen Pharmaceuticals, LLC.
 

AmPolGen Pharmaceuticals, LLC. is in engaged in research and development of gene targeted therapies. AmPolGen's current efforts focus on Sodium Phenylbutyrate (PB) and related compounds. Ampolgen was established in December of 2003, in order to engage in research, manufacturing, marketing, promotion, and sale of certain compounds which are known to effect expression of genes. The main efforts are concentrated on initiation, distribution and marketing of Sodium Phenylbutyrate as adjunctive therapy in the chronic management of patients with urea cycle disorder. more....